Skip to main content

Advertisement

Table 4 Relationship of baseline factors with pneumococcal and influenza immunologic responses

From: Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Baseline characteristic Pneumococcal vaccine Influenza vaccine
n/N (%) OR (95 % CI) n/N (%) OR (95 % CI)
Patients without protective antibody levels at baselinea
 MTX dose at baseline, mg/week None 2/4 (50.0) 0.3 (0.0, 3.0) 1/3 (33.3) 0.4 (0.0, 4.5)
>0–10 5/7 (71.4) 0.6 (0.1, 6.0) 17/25 (68.0) 1.6 (0.5, 4.7)
>10–15 19/25 (76.0) 0.8 (0.1, 4.8) 35/36 (62.5) 1.3 (0.5, 3.0)
>15 8/10 (80.0) 20/35 (57.1)
 Steroid at baseline Yes 19/26 (73.1) 0.9 (0.2, 3.4) 47/74 (63.5) 1.3 (0.6, 2.7)
No 15/20 (75.0) 26/45 (57.8)
 Age at main study baseline, years <55 28/35 (80.0) 3.3 (0.8, 14.2) 60/88 (68.2) 3.0 (1.3, 6.9)
≥55 6/11 (54.5) 13/31 (41.9)
Patients with protective antibody levels at baselinea
 MTX dose at baseline, mg/week None 2/6 (33.3) 0.6 (0.1, 4.1) 3/5 (60.0) 3.6 (0.5, 26.8)
>0–10 8/15 (53.3) 1.4 (0.4, 5.4) 3/12 (25.0) 0.8 (0.2, 3.9)
>10–15 9/25 (36.0) 0.7 (0.2, 2.3) 5/24 (20.8) 0.6 (0.2, 2.4)
>15 9/20 (45.0) 7/24 (29.2)
 Steroid at baseline Yes 16/37 (43.2) 1.1 (0.4, 2.9) 10/40 (25.0) 0.7 (0.2, 2.1)
No 12/29 (41.4) 8/25 (32.0)
 Age at main study baseline, years <55 23/47 (48.9) 2.7 (0.8, 8.6) 16/52 (30.8) 2.4 (0.5, 12.3)
≥55 5/19 (26.3) 2/13 (15.4)
Total populationb
 Protective antibody level at baseline Yes 28/66 (42.4) * 0.3 (0.1, 0.6) 18/65 (27.7) ** 0.2 (0.1, 0.5)
No 34/46 (73.9) * 73/119 (61.3) **
 MTX dose at baseline, mg/week None 4/10 (40.0) 0.5 (0.1, 2.2) 4/8 (50.0) 1.2 (0.3, 5.2)
>0–10 13/22 (59.1) 1.1 (0.4, 3.4) 20/37 (54.1) 1.4 (0.6, 3.2)
>10–15 28/50 (56.0) 1.0 (0.4, 2.4) 40/80 (50.0) 1.2 (0.6, 2.3)
>15 17/30 (56.7) 27/59 (45.8)
 Steroid at baseline Yes 35/63 (55.6) 1.0 (0.5, 2.2) 57/114 (50.0) 1.1 (0.6, 1.9)
No 27/49 (55.1) 34/70 (48.6)
 Age at main study baseline, years <55 51/82 (62.2) 2.8 (1.2, 6.8) *** 76/140 (54.3) 2.3 (1.1, 4.7) ***
≥55 11/30 (36.7) 15/44 (34.1)
  1. Based on the total population, regardless of protective antibody status at baseline. ORs and 95 % likelihood ratio CIs are based on a logistic regression model: vaccine response = baseline factor. ORs and CIs are presented for each category versus the reference category (baseline protective [no], MTX >15 mg/week, steroid [no], age ≥55 years). P-values are for confounding factors. Patients with >42 days between the pre- and post-vaccination sample dates were excluded from the analysis
  2. CI confidence interval, MTX methotrexate, OR odds ratio
  3. aMultivariate model; bbivariate model; *p = 0.0013; **p < 0.0001; ***p < 0.05